NSE: DIVISLAB | BSE: 532488

Expensive Performer

Download real time

6100.00 127.50 (2.13%)

289.2K NSE+BSE Volume

NSE 20 Mar, 2026 3:42 PM (IST)

161,935.8

Market Cap

Market Runner Up

Beta 1Year

Very Low volatility

Patent Expiry

Divi's Labs soars on Friday as Novo Nordisk's patent for Semaglutide is set to expire on Saturday See details

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Search Inside the pdf :

Divi's Laboratories Ltd.

20 Nov 2025, 12:00AM

6100.00

2.13%

Healthy CS traction and favorable mix boosted profitability even as generics remained soft

Accumulate: Divi's Laboratories Ltd.

Target

Deven Choksey

Divi’s enters the second half of FY26 with a healthy execution pipeline across Custom Synthesis, supported by multiple projects progressing through validation and expected to commercialize over the next 1–2 years.

Divi's Laboratories Ltd. is trading below all available SMAs

Divi's Laboratories Ltd.

10 Nov 2025

6100.00

2.13%

Divi's Labs (HOLD): Key molecule LOE to risk upside growth in Custom Synthesis

Hold: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported 3%/9%/11% above estimates. EBITDA margin reported 170 bps above estimates.

Number of FII/FPI investors decreased from 897 to 868 in Dec 2025 qtr

Divi's Laboratories Ltd.

10 Nov 2025

6100.00

2.13%

Divi's Laboratories (DIVI IN) Q2FY26 Result Update Peptides...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories .. has an average target of 6444.67 from 6 brokers.

Divi's Laboratories Ltd.

09 Nov 2025

6100.00

2.13%

Generics continue to drag growth, CS outlook unchanged

Sell: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

Divi’s Laboratories’ (Divi’s) Q2FY26 result was in line with our expectations on all fronts. Constant currency growth slowed down to ~10.8% vs. 15% QoQ and 18% in FY25.

Divi's Laboratories .. has an average target of 6444.67 from 6 brokers.

Divi's Laboratories Ltd.

08 Nov 2025

6100.00

2.13%

Operating leverage and CS strength support margins

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

Divi’s Laboratories (DIVI) delivered better-than-expected performance in 2Q with a 4%/10%/10% beat on revenue/EBITDA/PAT.

Divi's Laboratories Ltd. is trading below all available SMAs

Divi's Laboratories Ltd.

10 Sep 2025

6100.00

2.13%

DIVI' S LAB

Sell: Divi's Laboratories Ltd.

Recommendation Target

Geojit BNP Paribas

The company's outlook remains positive due to growth drivers such as increased traction from global innovators, a healthy pipeline of RFPs, expansion of scientific and technological capabilities, and steady growth in the nutraceutical business. Management highlighted persistent pricing pressures in generics and higher cost escalation compared to custom synthesis, weighing on margins. Regulatory delays of 12-24 months for peptides, contrast media, and Kakinada approvals restricted near term revenue conversion. Divi's also faces the risk of losing business related to...

Number of FII/FPI investors decreased from 897 to 868 in Dec 2025 qtr

Divi's Laboratories Ltd.

29 Aug 2025

6100.00

2.13%

Steady performance amid near-term headwinds; structural levers intact

Accumulate: Divi's Laboratories Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -14.9%/-22.7%, respectively, as we factor in subdued growth traction in Generic API segment, lower other income and higher depreciation expenses on account of higher investments in its facilities.

Number of FII/FPI investors decreased from 897 to 868 in Dec 2025 qtr

Divi's Laboratories Ltd.

07 Aug 2025

6100.00

2.13%

Divi's Laboratories (DIVI IN) Q1FY26 Result Update Margin...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q1FY26 EBITDA was 4% below our estimates led by lower margins despite higher CS revenues. We expect margins to improve, led by better product mix and stable raw material prices. Mgmt. suggested that moderation of raw material prices, increasing RFP's and commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. Our FY26E/FY27E EPS estimates stand marginally reduced by 3-4%. We expect 20% EBITDA CAGR and 12% PAT CAGR over FY25-27E. At CMP,...

Divi's Laboratories .. has an average target of 6444.67 from 6 brokers.

Divi's Laboratories Ltd.

06 Aug 2025

6100.00

2.13%

Divi's Labs (HOLD): Long-term supply agreements to offset macro headwinds

Hold: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Earnings below estimates, largely on price erosion pressure in generics offsetting the impact of Kakinada unit 3 on margins

Number of FII/FPI investors decreased from 897 to 868 in Dec 2025 qtr

Divi's Laboratories Ltd.

19 May 2025, 12:00AM

6100.00

2.13%

Divi's Laboratories (DIVI IN) Q4FY25 Result Update Margin...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q4FY25 EBITDA beat our estimates led by higher gross margin (62%; up 200 bps QoQ). We expect GMs to sustain, led by better product mix and stable raw material prices. Mgmt. suggested that moderation of raw material prices, increasing RFP's and commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. Our FY26E/FY27E EPS estimates broadly remain unchanged. We expect 22% EBITDA CAGR and 15% PAT CAGR over FY25-27E. At CMP, stock is trading at...

Number of FII/FPI investors decreased from 897 to 868 in Dec 2025 qtr

Is Divi's Laboratories Ltd. worth buying?

756 Votes:

Buy 78.17%

Sell 14.95%

Hold 6.88%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf